Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Bari – page 19

401 clinical trials in Bari, Italy across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Bari at a glance
401
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

401 trials in Bari

Open in trial search

Squamous cell carcinoma of head and neck

Not recruiting

Testing Drug Combinations with GSK4381562A, GSK6097608, GSK4428859 and Dostarlimab in Patients with PD-L1 Positive Head and Neck Cancer That Has Spread or Returned

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Cardiac failure

Not recruiting

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Respiratory syncytial virus infection+3

Not recruiting

Study on the Immune Response and Safety of RSVPreF3 OA Vaccine in Adults Aged 60+ with Respiratory Syncytial Virus Infections

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
  • Sponsor:GlaxoSmithKline Biologicals

Influenza

Not recruiting

Study on the Effectiveness of an MF59-Adjuvanted Influenza Vaccine Compared to a Non-Adjuvanted Vaccine in Adults Aged 65 and Older

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years · Healthy volunteers
  • Substances:A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227)
  • Sponsor:Seqirus UK Limited

Non-small cell lung cancer

Not recruiting

Study of Durvalumab and Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Dermatitis atopic

Not recruiting

Study on the Effects of GSK1070806 Injection in Adults with Moderate to Severe Atopic Dermatitis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Humanised IgG1 kappa monoclonal antibody against interleukin 18
  • Sponsor:Glaxosmithkline Research & Development Limited

Bladder cancer

Not recruiting

Study of Sasanlimab with BCG or Alone for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Not Responding to BCG

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Sasanlimab
  • Sponsor:Pfizer Inc.

Chronic kidney disease

Not recruiting

Study on Balcinrenone and Dapagliflozin for Adults with Chronic Kidney Disease and Albuminuria

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:AstraZeneca AB

Crohn's disease

Not recruiting

Study on Tulisokibart for Treating Moderate to Severe Crohn's Disease in Adults

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

Type 2 diabetes mellitus

Not recruiting

Study on the Effects of Maridebart Cafraglutide for Adults with Type 2 Diabetes

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Chronic kidney disease

Not recruiting

Study of BI 690517 and empagliflozin combination for protection of heart and kidneys in patients with chronic kidney disease

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Type 2 diabetes mellitus

Not recruiting

Evaluation of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Type 2 Diabetes Patients with High Cardiovascular Risk

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dulaglutide
  • Sponsor:Eli Lilly & Co.

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Bari

What the registry says about research in the country

01 Oncology Research

Studies focusing on innovative treatments for various cancers, including metastatic colorectal cancer, non-small cell lung cancer, and malignant pleural mesothelioma. Research evaluates new therapeutic approaches and drug combinations.

  • Colorectal Cancer Treatment Studies
  • Lung Cancer Therapies
  • Mesothelioma Management

Advanced clinical trials testing targeted therapies and immunotherapy approaches.

02 Infectious Disease Prevention

Investigations into vaccines and preventive treatments for various infectious conditions, particularly respiratory syncytial virus (RSV) and influenza. Studies include both pediatric and adult populations.

  • Vaccine Development
  • RSV Prevention
  • Influenza Protection

Focus on immunogenicity and safety in different age groups.

03 Hematologic Disorders

Research examining treatments for blood-related conditions, including chronic myeloid leukemia and acute myeloid leukemia. Studies evaluate novel therapeutic approaches and drug combinations.

  • Leukemia Treatments
  • Targeted Therapies
  • Clinical Outcomes

Emphasis on personalized treatment approaches and molecular targeting.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.